Benefit of Adding Metformin with A GLP-1

Combining GLP-1 agonists (such as liraglutide, semaglutide and tirzepatide) with metformin can offer several benefits for weight loss, especially in individuals with type 2 diabetes or obesity:

1. Synergistic Effects: GLP-1 agonists and metformin work through different mechanisms to lower blood sugar levels and promote weight loss. Combining them can have synergistic effects, enhancing their individual benefits.
2. Appetite Suppression: GLP-1 agonists are known to reduce appetite and promote feelings of fullness, which can lead to decreased food intake and subsequent weight loss. Metformin can also contribute to appetite suppression.
3. Glucose Control: Both GLP-1 agonists and metformin help to improve insulin sensitivity and reduce blood glucose levels. Better glucose control can prevent excessive hunger and cravings, aiding in weight loss efforts.
4. Fat Metabolism: GLP-1 agonists and metformin may influence lipid metabolism, promoting the breakdown of fat stores and inhibiting fat accumulation. This can contribute to overall weight loss and improvements in body composition. Metformin may inhibit the process of lipogenesis (creation of fat cells) and may also increase the body’s ability to burn fat for energy.
5. Cardiovascular Benefits: Both GLP-1 agonists and metformin have been shown to have cardiovascular benefits beyond their effects on weight loss, including reducing the risk of heart disease and stroke. Combining these medications may provide additional cardiovascular protection. In addition, metformin has been shown to lower LDL cholesterol and triglyceride levels, which are often elevated in people with obesity, positively contributing to overall cardiovascular health.
6. Improved gut microbiota: There is recent evidence that suggests that metformin may also positively impact the composition of gut bacteria, which can have implications for weight regulation and metabolic health.
7. Long-term Weight Maintenance: Studies suggest that the combination of GLP-1 agonists and metformin may help individuals achieve sustainable weight loss and prevent weight regain over the long term, especially when used in conjunction with lifestyle modifications such as diet and exercise.

Overall, the combination of GLP-1 agonists and metformin can be a powerful therapeutic strategy for achieving weight loss and improving metabolic health in individuals with type 2 diabetes or obesity. However, it’s essential to consult with a healthcare provider to determine the most appropriate treatment plan based on individual needs and medical history.

References

Paloma Rodriguez, MD, Kevin M. Pantalone, DO, ECNU, FACE, Marcio L. Griebeler, MD and Bartolome Burguera, MD, PhD., Should I consider metformin therapy for weight loss in patients with obesity but without diabetes? Cleveland Clinic Journal of Medicine September 2023, 90 (9) 545-548; DOI: https://doi.org/10.3949/ccjm.90a.22096

Popoviciu MS, Păduraru L, Yahya G, Metwally K, Cavalu S. Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials. Int J Mol Sci. 2023 Jun 21;24(13):10449. doi: 10.3390/ijms241310449. PMID: 37445623; PMCID: PMC10341852.